A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease

Inclusion Criteria

• •Are men and women ≥ 50 years of age with a diagnosis of Alzheimers disease.
• •Have a Mini-Mental State Exam between 5 and 14 inclusive.
• •Have been taking the medication memantine (ie., Namenda) for at least six months prior to this study.
• •Must have a caregiver who assists the patient at least five days per week for at least three hours per day, who can accompany patient to study visits, and who has an intimate knowledge of the patient's health states and personal care.